Doing business as Biothera Inc and Biothera Pharmaceuticals, the firm is organized around unlocking the promise of cancer immunotherapy. The firm's phase 2 drug Imprime PGG is a Pathogen Associated Molecular Patterning (PAMP) molecule that works like an immunological ignition switch to coordinate innate and adaptive immune responses. By more fully engaging the entire immune system, the firm can alter the protective microenvironment tumors often create to avoid detection and destruction making tje cancer cells more vulnerable to immune attack Imprime PGG enhances the efficacy of multiple classes of anti-tumor monoclonal antibodies, including tumor-targeting, anti-angiogenic and checkpoint inhibitors (PD-1, PD-L1 antibodies). Imprime PGG has strong proof of concept based on extensive clinical experience (>400 subjects to date) and widespread signals of efficacy across a range of tumor types. Unlike other PAMPs, Imprime PGG can be administered systemically and is well tolerated. Multiple clinical trials and translational research are underway to further optimize potential combinations with Imprime PGG whilele also providing additional data in support of a predictive biomarker that will inform patient selection in future clinical trials. With a broad intellectual property portfolio for Imprime PGG, Biothera is seeking to advance Imprime PGG into Phase 2/3 registration trials in multiple cancer indications in 2018.
